Ciprofloxacin: a novel therapeutic agent for iron overload?
Objective: Major thalassemia is one of the hematological diseases requiring multiple blood transfusions, which results in iron overload in the liver, heart and other organs. Current iron chelation therapy consists of intravenous (IV) deferoxamine and oral deferasirox and deferiprone. Although these...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2009-09-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | http://www.journalagent.com/z4/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-04796 |
| _version_ | 1797921915924381696 |
|---|---|
| author | Mitra Elmi Parvaneh Rahimi-Moghaddam Khosrou Abdi Mehdi Shafiee-Ardestani Massoud Mahmoudian |
| author_facet | Mitra Elmi Parvaneh Rahimi-Moghaddam Khosrou Abdi Mehdi Shafiee-Ardestani Massoud Mahmoudian |
| author_sort | Mitra Elmi |
| collection | DOAJ |
| description | Objective: Major thalassemia is one of the hematological diseases requiring multiple blood transfusions, which results in iron overload in the liver, heart and other organs. Current iron chelation therapy consists of intravenous (IV) deferoxamine and oral deferasirox and deferiprone. Although these chelators are effective, many side effects are reported. In the present study, the iron-chelating effect of ciprofloxacin with good oral absorption was investigated. Material and Methods: Thirty male albino Wistar rats were used for the study. Ciprofloxacin (7 or 14 mg/kg per day) was administered simultaneously with iron (0.03 g/kg per day) or after one-month administration of iron. Ciprofloxacin effect on iron absorption in the liver and heart was studied carefully using atomic absorption. Results: A significant decrease in the liver and heart iron following the ciprofloxacin (14 mg/kg per day) administration was observed, when compared with the control group. This ciprofloxacin-induced tissue iron depletion was more pronounced when it was administered simultaneously with iron, when it was administered for a longer duration (2 months rather than 1 month) and when it was given in higher doses (14 mg/kg per day). Conclusion: Administration of ciprofloxacin may help to decrease the burden of parenteral administration, thereby improving compliance and also the life expectancy of thalassemic patients. |
| first_indexed | 2024-04-10T14:23:00Z |
| format | Article |
| id | doaj.art-91aa51c7ff3540c2861d92b84ecbe55d |
| institution | Directory Open Access Journal |
| issn | 1300-7777 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T14:23:00Z |
| publishDate | 2009-09-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-91aa51c7ff3540c2861d92b84ecbe55d2023-02-15T16:09:14ZengGalenos Publishing HouseTurkish Journal of Hematology1300-77771308-52632009-09-012603114117Ciprofloxacin: a novel therapeutic agent for iron overload?Mitra ElmiParvaneh Rahimi-MoghaddamKhosrou AbdiMehdi Shafiee-ArdestaniMassoud MahmoudianObjective: Major thalassemia is one of the hematological diseases requiring multiple blood transfusions, which results in iron overload in the liver, heart and other organs. Current iron chelation therapy consists of intravenous (IV) deferoxamine and oral deferasirox and deferiprone. Although these chelators are effective, many side effects are reported. In the present study, the iron-chelating effect of ciprofloxacin with good oral absorption was investigated. Material and Methods: Thirty male albino Wistar rats were used for the study. Ciprofloxacin (7 or 14 mg/kg per day) was administered simultaneously with iron (0.03 g/kg per day) or after one-month administration of iron. Ciprofloxacin effect on iron absorption in the liver and heart was studied carefully using atomic absorption. Results: A significant decrease in the liver and heart iron following the ciprofloxacin (14 mg/kg per day) administration was observed, when compared with the control group. This ciprofloxacin-induced tissue iron depletion was more pronounced when it was administered simultaneously with iron, when it was administered for a longer duration (2 months rather than 1 month) and when it was given in higher doses (14 mg/kg per day). Conclusion: Administration of ciprofloxacin may help to decrease the burden of parenteral administration, thereby improving compliance and also the life expectancy of thalassemic patients.http://www.journalagent.com/z4/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-04796Thalassemiairon overloadciprofloxacinatomic absorptionchelator |
| spellingShingle | Mitra Elmi Parvaneh Rahimi-Moghaddam Khosrou Abdi Mehdi Shafiee-Ardestani Massoud Mahmoudian Ciprofloxacin: a novel therapeutic agent for iron overload? Turkish Journal of Hematology Thalassemia iron overload ciprofloxacin atomic absorption chelator |
| title | Ciprofloxacin: a novel therapeutic agent for iron overload? |
| title_full | Ciprofloxacin: a novel therapeutic agent for iron overload? |
| title_fullStr | Ciprofloxacin: a novel therapeutic agent for iron overload? |
| title_full_unstemmed | Ciprofloxacin: a novel therapeutic agent for iron overload? |
| title_short | Ciprofloxacin: a novel therapeutic agent for iron overload? |
| title_sort | ciprofloxacin a novel therapeutic agent for iron overload |
| topic | Thalassemia iron overload ciprofloxacin atomic absorption chelator |
| url | http://www.journalagent.com/z4/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-04796 |
| work_keys_str_mv | AT mitraelmi ciprofloxacinanoveltherapeuticagentforironoverload AT parvanehrahimimoghaddam ciprofloxacinanoveltherapeuticagentforironoverload AT khosrouabdi ciprofloxacinanoveltherapeuticagentforironoverload AT mehdishafieeardestani ciprofloxacinanoveltherapeuticagentforironoverload AT massoudmahmoudian ciprofloxacinanoveltherapeuticagentforironoverload |